加载中...
广告
发布时间 | 所属地区 | 所属机构 | 语言 |
---|---|---|---|
2024年05月09日 | -- | -- | 英语 (English) 中文 |
Published date: 8 May 2024 Last edited date: 8 May 2024 Open early engagement - This means that a procurement idea is currently active, it is in the early stage of development and judging interest from potential suppliers.
Closing date: 22 May 2024
Contract summaryIndustryMedical equipments, pharmaceuticals and personal care products - 33000000 Health services - 85100000 Pharmacy services - 85149000 Location of contractLS2 7EU Procurement referenceCF-2355600D0O000000rwimUAA Published date8 May 2024 Closing date22 May 2024 Contract typeService contract Contract is suitable for SMEs?Yes Contract is suitable for VCSEs?No DescriptionNHS England has published this Prior Information Notice (PIN) in relation to securing a supplier to apply for a major (type II) MHRA Marketing Authorisation variation for spironolactone. The variation is to add a new indication to the current licence (marketing authorisation) for treating acne in women. The Successful Supplier would need to prepare a dossier for the MHRA including a Risk Management Plan, apply for the licence variation, and if granted update their licence, Summary of Product Characteristics and patient information leaflet with the new indication and related data. More informationPrevious notice about this procurementLicence variation: Spironolactone for acne in women How to applyFollow the instructions given in the description or the more information section. About the buyerContact nameLeigh Parker AddressNHS England, Leeds
|
上一篇:
YPO - 001255 The Supply of Premium Handwriting Pens下一篇:
SSC - Market Engagement re Passivhaus Pilot Design and Build Construction猜你喜欢
加载中...
广告